Hepatitis B virus reactivation and alemtuzumab therapy.
Eur J Haematol
; 74(3): 254-8, 2005 Mar.
Article
en En
| MEDLINE
| ID: mdl-15693796
ABSTRACT
Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21-53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV-DNA clearance from blood within 8 weeks. The second patient (HBsAg and HBV-DNA seronegative, anti-HBs and anti-HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months after alemtuzumab. Two months after withdrawal of lamivudine, clinical and laboratory features of acute hepatitis B developed. Lamivudine therapy was restarted and a prompt recovery was obtained with HBsAg and HBV-DNA clearance.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Activación Viral
/
Leucemia Linfocítica Crónica de Células B
/
Virus de la Hepatitis B
/
Anticuerpos Monoclonales
/
Anticuerpos Antineoplásicos
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2005
Tipo del documento:
Article